Corporate AcquisitionOncology acquisition introduces a Phase II asset with blockbuster potential, exhibiting deeper, more durable responses and lower toxicity, hailed by analysts with an optimistic BUY rating and a heightened price objective.
Investor ConfidenceThe introduction of a significant share buyback program reflects strong confidence in long-term value creation, underlining the company's commitment to shareholder returns and growth acceleration.
Regulatory Support & Market AccessFDA supports the use of a surrogate marker which could enable a faster and cheaper route to market for Hexabody CD38, potentially influencing JNJ's opt-in decision positively.